Jaap C. Reijneveld trained as a physician and specialized in neurology and neuro-oncology in the Netherlands. During his training and early career he developed a strong interest in the patient’s perspective, leading to additional training in patient-reported outcomes and health-related quality of life research.

Apart from his clinical work, which still is a substantial (and favourite) part of his daily work, he has guided many medical residents and PhD candidates in their clinical and scientific development. He is frequently invited to speak at national and international conferences, sharing insights on patient-reported outcomes and supportive cancer care. His research work focuses on embedding patient-reported outcomes into clinical trials as well as routine care, ensuring that quality of life is considered alongside clinical outcomes. Through this work, he became more and more involved into the very influential, and world-leading EORTC Quality of Life Group, which has eventually resulted in his chairmanship of this group since 2021. This role facilitates him to further stress the need for patient-reported outcomes in both professional (e.g. ESMO, MASCC) and regulatory (e.g. FDA, EMA) organisations.

Throughout his professional trajectory, he has authored and co-authored almost 250 peer-reviewed publications on (neuro-)oncology and survivorship, with a particular focus on the long-term effects of treatment on physical and psychosocial wellbeing. By collaborating with multidisciplinary teams, he contributes to guideline development and to shaping supportive oncology care both nationally and internationally, with the ultimate goal that the patient-perspective will become leading in patient care and research.